Gut Kidney Axis in Enteric Hyperoxaluria
Part of paid clinical trials in New York, New York.
- Sponsor
- NYU Langone Health
- Study ID
- NCT05124886
- Status
- Recruiting
Conditions
- Enteric Hyperoxaluria
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Accepted
Interventions
- Moderately High Oxalate (MOx) Diet — OTHERDiets will contain 16% protein, 30% fat, and 54% carbohydrate, and are controlled in the amounts of calcium (400mg), oxalate (250mg), ascorbic acid (50mg), fiber (30 grams) and, other nutrients. Each controlled diet will be consumed for four days. On days of controlled diets, subjects will be provided with 2 liters of bottled water per day to ensure adequate hydration. After the controlled diet period, there will be a three-day washout period, where participants will consume Ad-lib diets supplemented with a daily intake of oxalate in the form of cooked spinach to be taken with breakfast daily for a total of 2 weeks.
Study Details
40 subjects with a confirmed diagnosis of IBD or \>6 months post-RYGB with a diagnosed USD event or kidney stone on imaging within the past three years and 40 healthy controls will be administered a high oxalate diet on Days 0-3 and Days 21-24 with a washout period on Days 4-7 and will be administered 250mg sodium oxalate on Days 8-20, via prepared spinach, from Weil Cornell Medicine's Clinical and Translational Science Center. Subjects will partake in four stool collections, four 24-h urine collections, two blood collections, and four sets of colonic permeability testing.
Key Dates
- Start date
- Nov 10, 2022
- Status verified
- May 2026
- Primary completion
- Mar 1, 2028
- Completion
- Mar 1, 2028
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Active Comparator: Healthy Controls
- Experimental: Enteric Hyperoxaluria
Primary Outcome Measure
Urinary Oxalate Levels (UOx) [ Time Frame: Day 2-3 ]
Central Contacts
- Lama Nazzal, MD212-263-2922
- David Goldfarb, MD212-263-0744
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | Lama Nazzal, MD Lama Nazzal, MD (PRINCIPAL_INVESTIGATOR) David Goldfarb, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
By research site